retatrutide phase 2 study results Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, 2 trial conducted in the USA Lilly orforglipron oral GLP-1 phase

However, their influence extends far beyond these primary benefits

Microdosing is taking much smaller amounts than the standard starting dose, sometimes just a fraction

In this trial involving adults with obesity, retatrutide demonstrated substantial weight reduction up to approximately 24% of body weight over 48 weeks a magnitude not previously observed with any approved pharmacological agent

We can answer your questions and help you find a plan that fits so you can move forward with confidence

As you journal how youre feeling, remember to consistently report back to your providers so they can give advice and even potentially adjust your treatment plan or GLP-1 medication to best suit your unique needs

The injection process begins with site selection and preparation